Joseph L. Malone

Joseph L. Malone

Auto-generated profile, based on publicly available information

Joseph L. Malone

University of Pittsburgh Medical Center, Pittsburgh, PA USA

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1995 in The American Journal of Medicine
Verified
Journal Article
Closed access
JMJoseph L. Malone
Joseph L. Malone
MWMark R. Wallace
Mark R. Wallace
BHByron B. Hendrick
Byron B. Hendrick
ALAnthony LaRocco
Anthony LaRocco
ETElizabeth Tonon
Elizabeth Tonon
EOEdward C. Oldfield
Edward C. Oldfield

16 May 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
TATesfay Abreha
Tesfay Abreha
JHJimee Hwang
Jimee Hwang
KTKamala Thriemer
Kamala Thriemer
YTYehualashet Tadesse
Yehualashet Tadesse
SGSamuel Girma
Samuel Girma
RPRic N. Price
Ric N. Price
Recent efforts in malaria control have resulted in great gains in reducing the burden of Plasmodium falciparum, but P. vivax has been more refractory. Its ability to form dormant liver stages confounds control and elimination efforts. To compare the efficacy and safety of primaquine regimens for radical cure, we undertook a randomized controlled trial in Ethiopia. Patients with normal glucose-6-phosphate dehydrogenase status with symptomatic P. vivax mono-infection were enrolled and randomly assigned to receive either chloroquine (CQ) or artemether-lumefantrine (AL), alone or in combination with 14 d of semi-supervised primaquine (PQ) (3.5 mg/kg total). A total of 398 patients (n = 104 in the CQ arm, n = 100 in the AL arm, n = 102 in the CQ+PQ arm, and n = 92 in the AL+PQ arm) were followed for 1 y, and recurrent episodes were treated with the same treatment allocated at enrolment. The primary endpoints were the risk of P. vivax recurrence at day 28 and at day 42. The risk of recurrent P. vivax infection at day 28 was 4.0% (95% CI 1.5%–10.4%) after CQ treatment and 0% (95% CI 0%–4.0%) after CQ+PQ. The corresponding risks were 12.0% (95% CI 6.8%–20.6%) following AL alone and 2.3% (95% CI 0.6%–9.0%) following AL+PQ. On day 42, the risk was 18.7% (95% CI 12.2%–28.0%) after CQ, 1.2% (95% CI 0.2%–8.0%) after CQ+PQ, 29.9% (95% CI 21.6%–40.5%) after AL, and 5.9% (95% CI 2.4%–13.5%) after AL+PQ (overall p < 0.001). In those not prescribed PQ, the risk of recurrence by day 42 appeared greater following AL treatment than CQ treatment (HR = 1.8 [95% CI 1.0–3.2]; p = 0.059). At the end of follow-up, the incidence rate of P. vivax was 2.2 episodes/person-year for patients treated with CQ compared to 0.4 for patients treated with CQ+PQ (rate ratio: 5.1 [95% CI 2.9–9.1]; p < 0.001) and 2.3 episodes/person-year for AL compared to 0.5 for AL+PQ (rate ratio: 6.4 [95% CI 3.6–11.3]; p < 0.001). There was no difference in the occurrence of adverse events between treatment arms. The main limitations of the study were the early termination of the trial and the omission of haemoglobin measurement after day 42, resulting in an inability to estimate the cumulative risk of anaemia. Despite evidence of CQ-resistant P. vivax, the risk of recurrence in this study was greater following treatment with AL unless it was combined with a supervised course of PQ. PQ combined with either CQ or AL was well tolerated and reduced recurrence of vivax malaria by 5-fold at 1 y. ClinicalTrials.gov NCT01680406

28 July 2011 in Malaria Journal
Verified
Journal Article
Open access
PDF file
JHJimee Hwang
Jimee Hwang
BABereket H Alemayehu
Bereket H Alemayehu
DHDavid Hoos
David Hoos
ZMZenebe Melaku
Zenebe Melaku
STSamuel G Tekleyohannes
Samuel G Tekleyohannes
SFScott Filler
Scott Filler
In vivo efficacy assessments of the first-line treatments for Plasmodium falciparum malaria are essential for ensuring effective case management. In Ethiopia, artemether-lumefantrine (AL) has been the first-line treatment for uncomplicated P. falciparum malaria since 2004.

1 May 1996 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
DSDonald R. Skillman
Donald R. Skillman
JMJoseph L. Malone
Joseph L. Malone
CDCatherine F. Decker
Catherine F. Decker
KWKenneth F. Wagner
Kenneth F. Wagner
RMRobert L. Mapou
Robert L. Mapou
MMMonte S. Meltzer
Monte S. Meltzer
The safety and tolerance of interferon alfa-n3 (IFN-αn3) was tested in 20 adults with asymptomatic human immunodeficiency virus type 1 (HIV-l) infection (>400 CD4Iymphocytes/mm3). IFN-αn3 was self-injected three times per week for 3–6 months: 5 patients received 1 mega-IU (MIU)/dose, 10 received 5 MIU/dose, and 5 escalated to their maximum tolerated dose. Subjects were evaluated every 2–4 weeks through 2 months after cessation of treatment. Neuropsychological tests were given at 3-month intervals. Markers of IFN activity, anti-IFN neutralizing antibodies, and antiviral response were measured monthly. IFNαn3 was safe and well tolerated: influenza-like symptoms were uncommon, laboratory toxicity was minimal, no adverse neurobehavioral side effects were evident, and no patient developed neutralizing antibodies against IFN. IFN-αn3 induced IFN-specific biologic responses and dose-related antiviral activity against HIV-1. Subjects showed stabilization of CD4 cells for > 20 months. IFN-αn3 should be studied in combination with other antiretroviral agents and in persons with more advanced HIV-1 infection.

15 June 2008 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
GTGeorge Turabelidze
George Turabelidze
MSMario Schootman
Mario Schootman
BZBao-Ping Zhu
Bao-Ping Zhu
JMJoseph L. Malone
Joseph L. Malone
SHSteven Horowitz
Steven Horowitz
EDUARDO J SIMOESEDUARDO J SIMOES
EDUARDO J SIMOES

15 November 2002 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MWMomtaz O. Wasfy
Momtaz O. Wasfy
RFRobert Frenck
Robert Frenck
TITharwat F. Ismail
Tharwat F. Ismail
HMHoda Mansour
Hoda Mansour
JMJoseph L. Malone
Joseph L. Malone
FMFrank J. Mahoney
Frank J. Mahoney
A total of 853 isolates of Salmonella serotype Typhi recovered from patients with typhoid fever who were admitted to a major infectious disease hospital in Cairo, Egypt, from 1987 through 2000 underwent antibiotic susceptibility testing to determine multiple-drug resistance. The observed resurgence of chloramphenicol susceptibility (P = .002) may suggest reuse of this drug for the treatment of typhoid fever in Egypt.